| HOME >> BIOLOGY >> TECHNOLOGY |
(1) (i) (18) (e)
Selling,
general and
administr-
ative 2,678 (33) (a) 2,646 2,360 (60) (a) 2,392
1 (e) 92 (e)
Write-off of
acquired
in-process
R&D - - 590 (590) (j) -
Amortization of
intangible
assets 221 (221) (d) - 224 (221) (d) -
(3) (k)
Other
charges 306 (39) (e) - 543 (543) (e) -
(267) (f)
------- ------- ------- ------- ------- -------
Total
operating
expenses 7,175 (745) 6,430 8,103 (1,742) 6,361
Operating
income 4,077 745 4,822 2,923 1,742 4,665
Interest and
other income
and (expense),
net 19 9 (g) 28 (20) 51 (n) 31
------- ------- ------- ------- ------- -------
Income before
income taxes 4,096 754 4,850 2,903 1,793 4,696
Provision for
income taxes 861 228 (o) 1,089 572 92 (p) 980
316 (q)
------- ------- ------- ------- ------- -------
Net income $3,235 $526 $3,761 $2,331 $1,385 $3,716
======= ======= ======= ======= ======= =======
Earnings per
share:
Basic $3.01 $3.50 $2.07 $3.30
Diluted (r) $3.00 $3.49 (a) $2.06 $3.29 (a)
Average shares
used in
calculation
'/>"/>
| SOURCE Amgen Copyright©2008 PR Newswire. All rights reserved |